EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Two randomised controlled phase 2 studies of the oral neutrophil elastase inhibitor alvelestat in alpha-1 antitrypsin deficiency

J Michael Wells iD, Ingrid L Titlestad, Hanan Tanash, Alice M Turner iD, Kenneth R Chapman iD, Umur Ş Hatipoğlu, Monica P Goldklang, Jeanine M D'Armiento, Cheryl S Pirozzi, M Bradley Drummond, Igor Z Barjaktarevic, Wissam M Chatila und 14 weitere

European Respiratory Journal · 2025

DOI: 10.1183/13993003.01019-2025 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Respiratory Journal, 2025. Verfasst von J Michael Wells und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA jmwells@uabmc.edu. Hauptthemen laut MEDLINE: alpha 1-Antitrypsin Deficiency, Leukocyte Elastase. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, NCATS NIH HHS, Mereo BioPharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder that causes emphysema from lack of the alpha-1 antitrypsin (AAT) serpin antiprotease, leading to protease–antiprotease imbalance. Weekly intravenous AAT therapy (augmentation) is the only specific treatment available. Alvelestat is an oral inhibitor of neutrophil elastase (NE) in development as a novel approach to AATD therapy. Here, we tested the safety and mechanistic efficacy of alvelestat in severe AATD.

Methods

We conducted two complementary, double-blind, randomised, placebo-controlled, 12-week trials, incorporating two doses of alvelestat in AATD. ATALANTa investigated 120 mg twice daily, including a subset of participants also receiving augmentation; ASTRAEUS tested 120 and 240 mg twice daily without augmentation. Primary and secondary end-points were the change in blood NE (the putative target) and its activity in AATD (Aα-Val 360 and desmosine/isodesmosine) as well as safety and tolerability.

Results

We enrolled 161 participants (63 in ATALANTa and 98 in ASTRAEUS). Blood NE was significantly suppressed in both studies at both doses, with the greatest effect (>90% suppression) at alvelestat 240 mg twice daily. There was no effect of alvelestat 120 mg on disease activity biomarkers, while 240 mg demonstrated significant reduction in Aα-Val 360 and desmosine. The most common adverse event was headache, particularly at the 240 mg dose. No safety signals of concern were detected.

Conclusions

Alvelestat effectively suppressed NE and its activity at both doses, but only the 240 mg twice-daily dose demonstrated relevant efficacy compared to placebo on disease activity biomarkers with a favourable safety profile. These findings support progression of the 240 mg twice-daily dose into a clinical end-point study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha 1-Antitrypsin DeficiencyLeukocyte ElastaseHumansMaleFemaleDouble-Blind MethodMiddle AgedAdultTreatment OutcomeAdministration, Oralalpha 1-AntitrypsinAged

Substanzen

Leukocyte Elastasealpha 1-Antitrypsin

Autor:innen und Institutionen

  • Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA jmwells@uabmc.edu.
  • UAB Lung Health Center, Birmingham, AL, USA.
  • Birmingham VA Healthcare System, Department of Veterans Affairs, Birmingham, AL, USA.
  • Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark.
  • Odin Respiratory Research Unit, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • Department of Respiratory Medicine, Skåne University Hospital, Malmö, Sweden.

ORCID-Profile: J Michael Wells, Alice M Turner, Kenneth R Chapman

Förderung

  • NHLBI NIH HHS
  • NCATS NIH HHS
  • Mereo BioPharma
  • National Center for Advancing Translational Sciences

Zitieren

APA

Wells, J. M., Titlestad, I. L., Tanash, H., Turner, A. M., Chapman, K. R., Hatipoğlu, U. Ş., Goldklang, M. P., D'Armiento, J. M., Pirozzi, C. S., Drummond, M. B., Barjaktarevic, I. Z., Chatila, W. M., Devine, M. S., Strange, C., Sandhaus, R. A., Parkin, J. M., Westfall, E., Lin, V. Y., Parks, R., …, & Stockley, R. A. (2025). Two randomised controlled phase 2 studies of the oral neutrophil elastase inhibitor alvelestat in alpha-1 antitrypsin deficiency. European Respiratory Journal. https://doi.org/10.1183/13993003.01019-2025

Vancouver

Wells JM, Titlestad IL, Tanash H, Turner AM, Chapman KR, Hatipoğlu UŞ, et al. Two randomised controlled phase 2 studies of the oral neutrophil elastase inhibitor alvelestat in alpha-1 antitrypsin deficiency. European Respiratory Journal. 2025. doi:10.1183/13993003.01019-2025

BibTeX
@article{Wells2025,
  author = {Wells, J Michael and Titlestad, Ingrid L and Tanash, Hanan and Turner, Alice M and Chapman, Kenneth R and Hatipoğlu, Umur Ş and Goldklang, Monica P and D'Armiento, Jeanine M and Pirozzi, Cheryl S and Drummond, M Bradley and Barjaktarevic, Igor Z and Chatila, Wissam M and Devine, Megan S and Strange, Charlie and Sandhaus, Robert A and Parkin, Jacqueline M and Westfall, Elizabeth and Lin, Vivian Y and Parks, Robin and Kuo, Hui-Chien and Ekue, Adzoa and Moffitt, Kelly L and Inshaw, Jamie and Aban, Inmaculada and Dransfield, Mark T and Stockley, Robert A},
  title = {Two randomised controlled phase 2 studies of the oral neutrophil elastase inhibitor alvelestat in alpha-1 antitrypsin deficiency},
  journal = {European Respiratory Journal},
  year = {2025},
  doi = {10.1183/13993003.01019-2025}
}
Kostenlos starten →